Clinical Trial Update: Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant [Phase 3]

View source ↗

Summary

Phase 3 trial comparing preemptive oral valganciclovir to intravenous ganciclovir for cytomegalovirus infections after bone marrow or peripheral blood stem cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• Cytovene-IV (ganciclovir)
• Valcyte (valganciclovir)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Cytomegalovirus Infections | Phase 3 | Status: TERMINATED